Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study

BMC Neurology

Shiva Maleki¹  Alireza Amin¹  Nahad Sedaghat²  Amir Parsa Abhari²  Hosein Nouri²  Masoud Etemadifar³  Mehri Salari⁴ 

[1] Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran;Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran;Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific, Education, and Research Network (USERN), Isfahan, Iran;Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran;Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

关键词: Demyelinating diseases;    Multiple sclerosis;    Disease progression;    Neuroinflammation;    COVID-19;   

DOI  :  10.1186/s12883-022-02590-9

来源: Springer

【 摘 要 】

BackgroundSome current evidence is pointing towards an association between COVID-19 and worsening of multiple sclerosis (MS), stressing the importance of preventing COVID-19 among people with MS (pwMS). However, population-based evidence regarding the long-term post-COVID-19 course of relapsing-remitting multiple sclerosis (RRMS) was limited when this study was initiated.ObjectiveTo detect possible changes in MS clinical disease activity after COVID-19.MethodsWe conducted an observational study from July 2020 until July 2021 in the Isfahan MS clinic, comparing the trends of probable disability progression (PDP) – defined as a three-month sustained increase in expanded disability status scale (EDSS) score – and relapses before and after probable/definitive COVID-19 diagnosis in a cohort of people with RRMS (pwRRMS).ResultsNinety pwRRMS were identified with definitive COVID-19, 53 of which were included in the final analysis. The PDPrate was significantly (0.06 vs 0.19, P = 0.04), and the relapse rate was insignificantly (0.21 vs 0.30, P = 0.30) lower post-COVID-19, compared to the pre-COVID-19 period. The results were maintained after offsetting by follow-up period in the matched binary logistic model. Survival analysis did not indicate significant difference in PDP-free (Hazard Ratio [HR] [95% CI]: 0.46 [0.12, 1.73], P = 0.25) and relapse-free (HR [95% CI]: 0.69 [0.31, 1.53], P = 0.36) survivals between the pre- and post-COVID-19 periods. Sensitivity analysis resulted similar measurements, although statistical significance was not achieved.ConclusionWhile subject to replication in future research settings, our results did not confirm any increase in the long-term clinical disease activity measures after COVID-19 contraction among pwRRMS.

【 授权许可】

CC BY